Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
High-dose vitamin D3 arm had significantly wider phase angle values at weeks 12 (MD = −0.461) and 24 (MD = −0.506), indicating healthier muscle cells
Source: Included RCTs and study characteristics. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Systematic review.
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Meta-analysis unclear · Blinding not applicable to this review · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Diet, nutrition, and hormone therapy for prostate cancer: a systematic review with implications for future interventions
Source: Article title.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Diet, nutrition, and hormone therapy for prostate cancer: a systematic review with implications for future interventions
Systematic review · JNCI Cancer Spectrum · 2026
Original publication title
Diet, nutrition, and hormone therapy for prostate cancer: a systematic review with implications for future interventions
© The Author(s) 2026. Published by Oxford University Press.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
Given excellent prostate cancer outcomes, comorbidity management is critical to survivorship. While hormone therapy or androgen deprivation therapy (ADT) is a mainstay of treatment, they can negatively impact quality of life and survivorship through cardiovascular, sexual, and metabolic effects. ADT-induced metabolic syndrome causes impaired glucose tolerance, muscle mass loss, and weight gain. This systematic review examined recent randomized clinical trials (RCTs) investigating the impact of diet and weight management strategies on mitigating ADT-related adverse effects.
Source: BackgroundAbstract: What methods does the paper describe?
A systematic review of RCTs (2015-2025) was performed using PubMed/Embase following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. To identify how diet and weight management impacts ADT symptoms, search terms included: “prostate cancer,” “diet,” “nutrition,” “glucagon-like peptide-1 receptor agonists” (GLP-1RA), and “ADT.” Risk of Bias 2 (ROB2) and Grading of Recommendations Assessment, Development, and Evaluation (GRADE) tools evaluated RCT quality.
Source: MethodsAbstract: Results
Of 2799 publications, 16 met inclusion/exclusion criteria (range, 23-96 patients/RCT). No RCTs had a high risk of bias or evaluated GLP-1RA. Outcomes included metabolic labs, body composition, and quality of life. Mediterranean and low-carbohydrate diets with exercise reduced cardiovascular and metabolic risk factors, with variable durability. Creatine trended toward increasing lean muscle mass. Multidisciplinary care and community involvement improved accountability and outcome durability.
Source: ResultsAbstract: Conclusions
This comprehensive review of diet and ADT in prostate cancer identified nutritional interventions that were safe, feasible, and may be recommended as part of prostate cancer treatment and survivorship. Future RCTs should evaluate optimal diet duration, longer follow-up, multidisciplinary patient support, and novel anti-metabolic therapies like GLP-1RA.
Source: ConclusionsAuthors’ abstract
Abstract
Background
Given excellent prostate cancer outcomes, comorbidity management is critical to survivorship. While hormone therapy or androgen deprivation therapy (ADT) is a mainstay of treatment, they can negatively impact quality of life and survivorship through cardiovascular, sexual, and metabolic effects. ADT-induced metabolic syndrome causes impaired glucose tolerance, muscle mass loss, and weight gain. This systematic review examined recent randomized clinical trials (RCTs) investigating the impact of diet and weight management strategies on mitigating ADT-related adverse effects.
Methods
A systematic review of RCTs (2015-2025) was performed using PubMed/Embase following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. To identify how diet and weight management impacts ADT symptoms, search terms included: “prostate cancer,” “diet,” “nutrition,” “glucagon-like peptide-1 receptor agonists” (GLP-1RA), and “ADT.” Risk of Bias 2 (ROB2) and Grading of Recommendations Assessment, Development, and Evaluation (GRADE) tools evaluated RCT quality.
Results
Of 2799 publications, 16 met inclusion/exclusion criteria (range, 23-96 patients/RCT). No RCTs had a high risk of bias or evaluated GLP-1RA. Outcomes included metabolic labs, body composition, and quality of life. Mediterranean and low-carbohydrate diets with exercise reduced cardiovascular and metabolic risk factors, with variable durability. Creatine trended toward increasing lean muscle mass. Multidisciplinary care and community involvement improved accountability and outcome durability.
Conclusions
This comprehensive review of diet and ADT in prostate cancer identified nutritional interventions that were safe, feasible, and may be recommended as part of prostate cancer treatment and survivorship. Future RCTs should evaluate optimal diet duration, longer follow-up, multidisciplinary patient support, and novel anti-metabolic therapies like GLP-1RA.
Publication and source details
Original title: Diet, nutrition, and hormone therapy for prostate cancer: a systematic review with implications for future interventions
Isabella Pahulu; Matthew Calumpit; Paul Tominez; Jonathan J Shih; Sasha Ebrahimi; Nicole V Deville; Raynald Samoa; Tannaz Moin; Mina S Sedrak; Luca F Valle; Michael Steinberg; Amar U Kishan; Patricia A Ganz; Kekoa Taparra
JNCI Cancer Spectrum · 2026
Corresponding author: Kekoa Taparra, MD, PhD, MPH, Department of Radiation Oncology, David Geffen School of Medicine, UCLA, Department of Health Policy and Management, Fielding School of Public Health, UCLA, 200 Medical Plaza Driveway, Suite #B265, Medical Plaza, Los Angeles, CA 90095, United States (ktaparra@ucla.edu).© The Author(s) 2026. Published by Oxford University Press.2026https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-10T23:52:56.742522+00:00
DOI: 10.1093/jncics/pkag014 · PMC12972670